A supervised adverse drug reaction signalling framework imitating Bradford Hill’s causality considerations by Reps, Jenna M. et al.
Reps, Jenna M. and Garibaldi, Jonathan M. and 
Aickelin, Uwe and Gibson, Jack E. and Hubbard, 
Richard B. (2015) A supervised adverse drug reaction 
signalling framework imitating Bradford Hill’s causality 
considerations. Journal of Biomedical Informatics, 56 . 
pp. 356-368. ISSN 1532-0480 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/30450/1/revisions%281%29.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the University of Nottingham End User licence and may 
be reused according to the conditions of the licence.  For more details see: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
00 (2015) 1–27
A Supervised Adverse Drug Reaction Signalling Framework
Imitating Bradford Hill’s Causality Considerations
Jenna Marie Repsa,∗, Jonathan M. Garibaldia, Uwe Aickelina, Jack E. Gibsonb, Richard B.
Hubbardb
aSchool of Computer Science, University of Nottingham, NG8 1BB, UK
bDivision of Epidemiology and Public Health, University of Nottingham, UK
Abstract
Big longitudinal observational medical data potentially hold a wealth of information and have been recognised as potential sources
for gaining new drug safety knowledge. Unfortunately there are many complexities and underlying issues when analysing lon-
gitudinal observational data. Due to these complexities, existing methods for large-scale detection of negative side effects using
observational data all tend to have issues distinguishing between association and causality. New methods that can better discrimi-
nate causal and non-causal relationships need to be developed to fully utilise the data.
In this paper we propose using a set of causality considerations developed by the epidemiologist Bradford Hill as a basis for
engineering features that enable the application of supervised learning for the problem of detecting negative side effects. The
Bradford Hill considerations look at various perspectives of a drug and outcome relationship to determine whether it shows causal
traits. We taught a classifier to find patterns within these perspectives and it learned to discriminate between association and
causality. The novelty of this research is the combination of supervised learning and Bradford Hill’s causality considerations to
automate the Bradford Hill’s causality assessment.
We evaluated the framework on a drug safety gold standard know as the observational medical outcomes partnership’s non-
specified association reference set. The methodology obtained excellent discriminate ability with area under the curves ranging
between 0.792-0.940 (existing method optimal: 0.73) and a mean average precision of 0.640 (existing method optimal: 0.141).
The proposed features can be calculated efficiently and be readily updated, making the framework suitable for big observational
data.
c© 2011 Published by Elsevier Ltd.
Keywords: Big data, pharmacovigilance, longitudinal observational data, causal effects
1. Introduction
Side effects of prescription drugs, also known as adverse drug reactions (ADRs), occur unpredictably and present
a major healthcare issue. It is possible that a generally healthy individual may take a prescription drug for a minor
problem and end up with a potentially life threatening ADR. As a consequence, it is essential to monitor all marketed
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drugs and develop methods that are capable of identifying ADRs at the earliest possible point in time. The potential
benefits of utilising longitudinal observational data for detecting (also known as signalling) ADRs have been high-
lighted [1]. However, unsupervised methods developed to signal ADRs using longitudinal observational data have
been found to obtain high false positive rates consistently across data sources [2, 3]. This is due to the complexities of
observational data, such as missing data and confounding, making it difficult for the methods to distinguish between
association and causality. Reference sets detailing known ADRs and non ADRs have been created to aid the develop-
ment of ADR signalling methods for longitudinal data by enabling a fair evaluation of the methods’ ADR signalling
performances [4]. However, the creation of reference sets now presents the opportunity of generating labelled data
and developing a supervised framework that can be applied to longitudinal observational data to signal ADRs. The
success of a supervised framework relies on identifying suitable features for discriminating between causal and non-
causal relations. The Bradford Hill causality considerations are a collection of nine factors that are often considered
by experts to evaluate whether a drug and health outcome pair may correspond to an ADR [5, 6, 7]. Therefore, the
Bradford Hill causality considerations seem an ideal basis for engineering suitable causal discriminative features to
be used as input to train an ADR signalling classifier. The aim of this paper is to investigate whether such a classifier
can be trained to successfully automate the process of using the Bradford Hill causality considerations to identify
causality.
Our proposed supervised Bradford Hill’s methodology is evaluated by considering the problem of signalling ADRs
that occur shortly after being prescribed a medication. The data used in this study is a large UK electronic healthcare
database that contains medical records for millions of patients in the UK. The database is over 300GB in size, there-
fore it is important to consider the efficiency of the feature engineering. The Bradford Hill’s causality considerations
were developed by an epidemiologist in the 60s with experience in identifying causal relationships between drugs and
health outcomes. They have been successfully implemented, by the process of manual review, as a means to determine
causality in many epidemiological studies [8]. The considerations state that nine factors should be considered when
assessing causality between a drug and health outcome. The factors are: i) association strength, ii) temporality, iii)
consistency, iv) specificity, v) biological gradient, vi) experimentation, vii) analogy, viii) coherence and ix) plausi-
bility. As longitudinal observational databases contain data that can give insight into many of these considerations,
we should take advantage of the data available to create a supervised signal detection framework that can imitate the
causality review process.
The problem of identifying ADRs, has often relied on the use of spontaneous reporting system (SRS) data. SRS
data are composed of reported cases where somebody has suspected that a drug caused an ADR [9]. Common methods
for detecting ADRs using SRS data are the disproportionality methods [10] that calculate a measure of association
strength between the drug and health outcome based on inferring approximate background rates using all the reports.
However, it is not possible to calculate the actual background incidence rates corresponding to the drug or health
outcome using SRS data. Issues with under-reporting [11] can limit the ability to detect ADRs using SRS data
and consequently, there has been an interest in using longitudinal observational data to aid ADR detection. Recent
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advances in using SRS data for signalling ADRs have focused on utilising all the SRS data and have considered non-
association strength features [12, 13]. It was shown that considering a variety of features lead to an improvement in
ADR detection compared to standard methods [12]. However, this idea is currently unexplored for ADR detection
using longitudinal observational databases, although there has been preliminary work suggesting Bradford Hill based
features may add a new perspective for analysing electronic healthcare records [14].
Longitudinal observational data has been a recent focus of attention for extracting new drug safety knowledge
due to it being a cheaper and often safer alternative to experimentation such as randomised controlled trials. Existing
method for signalling ADRs using longitudinal observational databases include adapted disproportionality methods
[15, 16], association rule mining techniques [17, 18], or adaptions of epidemiological studies [19]. All the large scale
signalling methods are unsupervised, focus mostly on the measure of association strength and tend to have a high false
positive rate in real life data [2, 3], although some supervised techniques have been developed for specific cases. In
[20], an ensemble technique combining simple epidemiology study designs to identify paediatric ADRs was shown to
perform well. This suggested that incorporating supervised learning for ADR detection might lead to the improvement
of signalling ADRs. For supervised learning to be fully utilised in this field, it is important to identify suitable features
for the model. This motivates the idea of using a standard set of causal considerations widely implemented by experts
in the field of epidemiology as a basis to engineer features. Numerous observational databases, including electronic
healthcare records, tend to have hierarchies in the data recording [21, 22]. It may be important to consider the
hierarchies when searching for causal relationships because the relationship may be non-obvious when considering a
high level item due to it occurring less frequently, but obvious when an abstract perspective is taken. If not taken into
consideration, the hierarchal nature of the databases may weaken a signal. Therefore, we also propose features based
on medical event coding hierarchies.
Outside of the field of drug safety, existing methods developed with the aim of identifying causal relationships
within longitudinal observational data are often based on Bayesian networks [23]. Due to the complexity of creating a
complete Bayesian network, many of the proposed methods are considered inappropriate for ‘big’ data [24]. However,
constraint-based causal detection has been suggested as a means to handle ‘big’ data by applying metaheaurisics that
reduce the problem space [25]. Unfortunately these methods cannot overcome the common issues found within med-
ical longitudinal data such as selection bias and do not consider hierarchal structures, and are therefore not currently
suitable for signalling ADRs.
The continuation of this paper is as follows. Section 2 details the database used within this research and the
proposed supervised Bradford Hill framework. In section 3 we present the results of the supervised Bradford Hill
framework’s performance for signalling ADRs using a real database containing millions of UK patient records. The
implications of the results are discussed in section 4. The paper concludes with section 5.
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2. Materials and Methods
2.1. THIN Database
The data used in this paper were extracted from The Health Improvement Network (THIN) database, an electronic
healthcare database containing UK primary care records for over 3.7 million active patients [26] (www.thin-uk.com).
As the database contains time stamped records of medical events (e.g., myocardial infarction or vomiting) and drug
prescriptions, each patient’s medical state can be observed over time and temporal relationships between drugs and
medical events can be identified. The THIN data used in this research contained over 200 million medical records and
over 350 million prescription records
The THIN database consists of heterogeneous data with multiple hierarchal structures. The database contains
three key tables; the patient table, the medical table and the therapy table. For privacy reasons the patients’ identities
are not stored in the database, instead, each patient is assigned a unique reference known as the patientID that is
used to determine which patient each record in the database corresponds to. The patient table contains information
about each patient such as their date of birth, gender and date of registration or date of death (if they have died). The
medical and therapy tables contain time stamped records of any medical or therapy event experienced by the patients,
respectively. The database is normalised such that medical event descriptions and drug details are stored into separate
tables and linked with unique references. The unique reference of a medical event is known as the Read code [22] and
the unique reference of a drug is known as a drugcode.
The Read codes have a hierarchical coding system encompassing five levels of specificity, with level one Read
codes representing very general events and level five Read codes representing very specific events. The level of a
Read code is determined by its length. An example of a level one Read code is ‘1’ and an example of a level 5 Read
code is ‘11a1b’. The level 1 Read code ‘G’ is the parent of any Read code starting with ‘G’. For example, the level 1
Read code ‘G’ representing the medical event ‘Circulatory system disease’, it is the parent of the Read codes:
Level 2 : ‘G5’ - ‘Other forms of heart disease’
Level 3 : ‘G57’ - ‘Cardiac dysrhythmias’
Level 4 : ‘G57y’ - ‘Other cardiac dysrhythmias’
Level 5 : ‘G57y1’ - ‘Severe sinus bradycardia’
We define an equivalence relationship between Read codes as, Readcodem
k
∼ Readcoden if the level k parent of
Readcodem is the same as the level k parent of Readcoden. For example, G51
2
∼ G5724. Prescription drugs are
recorded via a drugcode and have an associated British National Formula (BNF) code [27]. The BNF code also has
a hierarchal structure and can be used to identify similar drugs. In the THIN database there are more than 66, 000
drugcodes and 100, 000 Read codes.
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2.1.1. THIN Processing
Care needs to be taken with newly registered patients as patients can move to new general practices at any point
in their life and may have existing medical conditions that get recorded when they join the new practice. Newly
registered patients have the potential to bias results as doctors may record medical events that are pre-existing, but
these events will have an incorrect timestamp. It has been shown that the probability of pre-existing medical events
being recorded into the THIN database for newly registered patients is significantly reduced after a year of the patient
being registered [28]. Consequently, to prevent newly registered patients biasing results, the first year after registration
is ignored in this study. We also ignore drug prescription records that occurred within the final month of the latest
THIN data collection date as including these might cause under-reporting.
2.2. Supervised ADR signalling Framework
The supervised ADR framework (SADR) involves three steps. Figure 1 presents the flowchart of the framework,
showing how the framework is used to signal new ADRs once a classifier is trained. The first step is to extract the
dataset based on existing reference sets developed for evaluating signal detection methods for longitudinal obser-
vational data [29]. This step involves identifying the drug-health outcome pairs and their label (e.g., is the drug a
known ADR or non-ADR of the health outcome?). The second step of the SADR framework is to implement feature
engineering to combine existing drug safety measure features and create novel features that cover the Bradford Hill
strength, temporality, specificity, experimentation and biological gradient considerations. The other considerations
were not included due to the information not generally being available in a single longitudinal observational database.
Features specific to the hierarchal structures of medical event codings are also proposed. The third step is training a
binary classifier using the reference set labels and Bradford Hill consideration based features to produce a supervised
ADR signal detection model that can discriminate between causality and association. To evaluate the suitability of the
various features we will train the classifier on a subset of the labelled data and validate the classifier on the remaining
subset of the labelled data to investigate the agreement between the prediction and truth and ensure the classifier is
generalizable (i.e., should perform as well on new data). Due to limited definitive knowledge of known ADRs and
non-ADRs, this is the best approach to determine the performance of the classifier for signalling ADRs. In this paper
we use the random forest binary classifier as this was shown to perform well for the THIN data in previous work [20]
and this was also supported by preliminary results.
The SADR framework is only applied to drug and Read code pairs where the Read code occurred for 3 or more
patients within the month of the drug prescription. This restriction is due to this paper focusing on ADRs that occur
shortly after the drug is ingested, so a month period is a trade off between ensuring the ADR is recorded while reducing
the amount of noise. If the Read code occurs for less than 3 patients within the month after the drug then it would be
very difficult to statistically show the corresponding medical event is an ADR and the three or more limit is a common
threshold applied in pharmacovigilance [30].
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Figure 1: The overall flowchart of the SADR framework
2.2.1. Step 1: Create Dataset
The observational medical outcomes partnership (OMOP) have provided a non-specified association (NSA) ref-
erence set containing drug-health outcome of interest (HOI) pairs known to correspond to ADRs or non-ADRs [29].
This reference set was generated specifically for evaluating signal generating methods to enable a fair comparison.
This set states whether the HOI occurs shortly after drug exposure, or after long term exposure.
Matching the OMOP NSA reference set with the THIN data caused some issues. THIN record their prescriptions
using a unique drug coding system (a transformation of the multilex code) and there is currently no way to map the
THIN prescription coding to the OMOP reference set coding without requiring extensive manual work from the THIN
staff. To overcome this issue we managed to identify suitable BNF codes for the OMOP drugs and used the BNF as
a way to match the OMOP drug and the THIN drugcodes. There is a mapping between the THIN Read codes and
the OMOP health outcome codes, however this is not one-to-one as the Read clinical coding suffers from redundancy.
Consequently, it was common to have multiple drug-Read code pairs for each drug-HOI pair.
There were issues finding a suitable BNF code for Amphotericin. We could not find any prescriptions of drugs
with the BNF code 05020300 (Amphotericin) in the THIN data as Amphotericin was recorded with the BNF codes
05020000, 13100200 or 12030200 but these also corresponded to non-Amphotericin drugs. Therefore we excluded
Amphotericin from the analysis. Table 1 shows the drugs’ BNF mappings used and the number of HOI or Read codes
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Table 1: Mapping between OMOP drugs and BNF codes used to map OMOP drugs to THIN drugs.
Count
Drug BNF HOI Read
OMOP ACE Inhibitor 02.05.05.01 527 566
OMOP Antibiotics 05.01.08.00 292 301
OMOP Antibiotics 05.01.03.00 232 243
OMOP Antibiotics 05.01.05.00 299 315
OMOP Antiepileptics 04.08.01.00 417 440
OMOP Benzodiazepines 04.01.02.00 345 371
OMOP Benzodiazepines 04.08.02.00 6 6
OMOP Beta blockers 02.04.00.00 499 528
OMOP Bisphosphonates 06.06.02.00 282 301
OMOP Tricyclic antidepressants 04.03.01.00 443 478
OMOP Typical antipsychotics 04.02.01.00 307 332
OMOP Typical antipsychotics 04.06.00.00 7 7
OMOP Typical antipsychotics 23.00.00.00 1 1
OMOP Warfarin 02.08.02.00 327 345
paired with each drug in the dataset. It can be seen there were multiple Read codes for each HOI. As the performance
of a classifier is likely to improve with a larger training set, we decided to keep the drug-Read code pairs rather than
aggregating them into drug-HOI pairs, although this does means some of the signals may be weaker.
At this point we had a list of 4249 drug-Read code pairs, drugi-Readcode j, and their ground truth labels (e.g.,
whether the pair is a known ADR or non-ADR). The next step was to generate suitable features for each pair.
2.2.2. Step 2: Features Engineering
Features based on the five factors of the Bradford Hill considerations and specific to the hierarchal medical event
coding structures were calculated per drug-Read code pair. A summary of these features can be found in Table A.7
within Appendix A. A total of 17 different features were proposed based on the Bradford Hill considerations and
another 10 are proposed based on hierarchal structures. For some of the factors we considered numerous similar
features that may be correlated as this is the first extensive study combining features based on the Bradford Hill
considerations and it is not know which features may be more suitable. We investigated the importance of the features
based on the average total decrease in Gini impurity gained by splitting the tree’s node on a particular feature within
the random forest (the importance function in the R randomForest library) [31].
The data used to generate the features includes the unique ID of the patient, the patient’s age, the patient’s gender,
7
/ 00 (2015) 1–27 8
the dosage of the drug and a value indicating how noisy the data point may be due to how many other drugs the patient
was prescribed in the month before and after the prescription. To calculate the features we extract certain records from
the THIN database,
• x
i,.
k
= (patientID, age, gender, dosage, noise) is a vector corresponding the details of the kth prescription of
drugi within the database.
• y
i,.
k
= (patientID, age, gender, dosage, noise) is a vector corresponding the details of the kth prescription of
drugi within the database but where there has been no recording of the same drugcode within the past 13
months for the patient.
• z
i,.
k
= (patientID, age, gender, dosage, noise) is a vector corresponding the details of the kth prescription of
drugi within the database but where there has been no recording of any drug from the same drug family within
the past 13 months for the patient.
The age is the patient’s age when prescribed the drug, the gender is 1 if male and 0 otherwise and the dosage is the
dosage of the prescription. The noise value corresponds to the number of other drugcodes that are prescribed for the
same patient within 30 days before and 30 days after the drug prescription of interest. The instances when a patient
experiences a medical event (Readcode j) within a hazard period centred on the drug (drugi) are,
• x
[u,v],i, j
k
= (patientID, age, gender, dosage,
noise, f irst3, f irst4) is a vector corresponding the details of the kth time Readcode j is recorded between u and
v days after the drugi is recorded within the database.
• y
[u,v],i, j
k
= (patientID, age, gender, dosage,
noise, f irst3, f irst4) is a vector corresponding the details of the kth time Readcode j is recorded between u and
v days after drugi is recorded for the first time in 13 months for the patient within the database.
• z
[u,v],i, j
k
= (patientID, age, gender, dosage,
noise, f irst3, f irst4) is a vector corresponding the details of the kth time Readcode j is recorded between u and
v days after the drugi is recorded and no drug from the same drug family is recorded for the patient within the
previous 13 months within the database.
In the above vectors the first five elements correspond to the same details as the prescription vector but the binary
element first3 is 1 iff there are no previous recordings of any Readcode
3
∼ Readcode j for the patient and first4 is 1 iff
there are no previous recordings of any Readcode
4
∼ Readcode j for the patient.
We define Xi,. = {xi,.
1
, ..., x
i,.
m} to be the set of all vectors detailing each prescription of drugi, so |X
i,.| is the total
number of prescriptions of drugi. Y
i,. and Zi,. are similarly used to denote the set of vectors detailing each prescription
of drugi such that the drug has not been prescribed within the previous 13 months or a similar drug has not been
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recorded within the previous 13 months respectively. We define X[u,v],i, j = {x
[u,v],i, j
1
, ..., x
[u,v],i, j
m }, so the cardinality of
X[u,v],i, j (denoted |X[u,v],i, j|) corresponds to the number of prescription of drugi that have the Readcode j recorded within
their [u, v] hazard period. Similarly, Y [u,v],i, j = {y
[u,v],i, j
1
, ..., y
[u,v],i, j
m } and Z
[u,v],i, j = {z
[u,v],i, j
1
, ..., z
[u,v],i, j
m }.
The proposed features are,
(i) Strength - This factor represents the association strength, as generally a causal relationship is likely to have a large
value of association, so a higher association means a higher likelihood of a causal relationship. A common way to
calculate the association strength for drug safety (which could also be applied in general) is by investigating variation
in the risk of experiencing a health outcome in patients exposed to a drug (or antecedent) and those unexposed.
The risk of Readcode j during a defined time period after drugi for a specific set of THIN records is simply the
number of prescriptions of drugi in the set where Readcode j was recorded within a defined time period after drugi
divided by the total number of prescriptions of drugi in the set. Similarly, the risk of Readcode j during a defined
time period after any drug other than drugi for a specific set of THIN records is the number of prescriptions of any
non-drugi drug in the set where Readcode j was recorded within the defined time period afterwards divided by the
total number of prescriptions of any non-drugi drug in the set.
The risk difference is the risk of the health outcome in the group of patients exposed to the drug minus the risk of
the health outcome in some control group of patients. The risk difference used in this study is the risk of Readcode j
during the 1 to 30 day period after drugi minus the risk of the Readcode j during the 1 to 30 day period after any other
drug. The 1 to 30 day period was chosen as we are interested in acutely occurring ADRs, but this period chould be
adjusted to signal ADRs that take longer to occur. The formal calculations for the different set of THIN records X,Y
and Z are,
Attr
i, j
1
= (|X[1,30],i, j|/|Xi,.|) − (
∑
s,i
|X[1,30],s, j|/
∑
s,i
|Xs,.|)
Attr
i, j
2
= (|Y [1,30],i, j|/|Y i,.|) − (
∑
s,i
|Y [1,30],s, j|/
∑
s,i
|Y s,.|)
Attr
i, j
3
= (|Z[1,30],i, j|/|Zi,.|) − (
∑
s,i
|Z[1,30],s, j|/
∑
s,i
|Z s,.|)
(1)
(ii) Specificity - The specificity factor has been interpreted in many ways. The original interpretation is that it
investigates whether the drug is observed to cause one or many medical events. There has been a debate regarding
this consideration as some researchers believe it to be generally uninformative [32]. However, it has been argued that
it can have a use for identifying causal relationships [33]. Some researchers consider the specificity to correspond to
how specific the relationship is, for example is the association mainly found in a certain age and gender subpopulation
or is the drug associated to a very specific medical event? One way to easily calculate whether the association tends
to occur for a specific age range is to calculate the average age of the patients experiencing the medical event within
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the 1 to 30 day period after the drug and compare this to the average age of all the patients prescribed the drug,
Attr
i, j
4
= (m ×
n∑
k=1
x
[1,30],i, j
k2
)/(n ×
m∑
k=1
x
i,.
k2
)
Attr
i, j
5
= (m ×
n∑
k=1
y
[1,30],i, j
k2
)/(n ×
m∑
k=1
y
i,.
k2
)
Attr
i, j
6
= (m ×
n∑
k=1
z
[1,30],i, j
k2
)/(n ×
m∑
k=1
z
i,.
k2
)
(2)
Another specificity consideration is whether the association occurs more for one specific gender, an easy way to
calculate a measure for this is to compare the fraction of patient that experience the medical event within the 1 to 30
day period after the drug who are male divided by the fraction of patients that are prescribed the drug who are male,
Attr
i, j
7
= (m ×
n∑
k=1
x
[1,30],i, j
k3
)/(n ×
m∑
k=1
x
i,.
k3
)
Attr
i, j
8
= (m ×
n∑
k=1
y
[1,30],i, j
k3
)/(n ×
m∑
k=1
y
i,.
k3
)
Attr
i, j
9
= (m ×
n∑
k=1
z
[1,30],i, j
k3
)/(n ×
m∑
k=1
z
i,.
k3
)
(3)
and the final specificity feature is how specific the medical event is, this can be determined by the level of the Read
code. We create a feature indicating whether the Read code is a level 5, level 4, level 3 or level 2 Read code,
Attr
i, j
10
=

5 if Readcode j is a level 5 Read code
4 if Readcode j is a level 4 Read code
3 if Readcode j is a level 3 Read code
2 if Readcode j is a level 2 Read code
1 otherwise
(4)
(iii) Temporality - This factor investigates the direction of the relationship. If the relationship is causal then
the drug must occur before the medical event. In [34], the authors used temporality features to train a classifier to
discriminate between indicators and adverse events. This has also been seen in [35], where the authors used the
temporality measures to identify off-target drugs. Similarly, for this factor we consider how often Readcode j occurs
during the 1 to 30 day period after a prescription of drugi compared to the 1 to 30 day period before drugi,
Attr
i, j
11
= |X[1,30],i, j|/|X[−30,−1],i, j|
Attr
i, j
12
= |Y [1,30],i, j|/|Y [−30,−1],i, j|
Attr
i, j
13
= |Z[1,30],i, j|/|Z[−30,−1],i, j|
(5)
(iv) Biological gradient - In the context of detecting ADRs this relates to the dosage of the drug. It is generally
the case, but not always [36], that there is a monotonic increasing relationship between the dosage of the drug and
10
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the probability of experiencing the ADR [37]. Due to this, Bradford Hill’s criteria suggest that the dosage should
be considered when determining causality, as medical events that occur more with high dosages are more likely to
correspond to ADRs. A simple and efficient feature of the biological gradient criterion is to compare the average
dosage given to patients who experienced the medical event within a month of taking the drug divided by the average
dosage of the patients prescribed the drug,
Attr
i, j
14
= (m ×
n∑
k=1
x
[1,30],i, j
k4
)/(n ×
m∑
k=1
x
i,.
k4
) (6)
Attr
i, j
15
= (m ×
n∑
k=1
y
[1,30],i, j
k4
)/(n ×
m∑
k=1
y
i,.
k4
) (7)
Attr
i, j
16
= (m ×
n∑
k=1
z
[1,30],i, j
k4
)/(n ×
m∑
k=1
z
i,.
k4
) (8)
It could be possible to generate an improved feature of the biological gradient by investigating the correlation between
the time to the health outcome and the dosage. Unfortunately this would be inefficient when analysing hundreds or
thousands of drug and health outcome pairs, so the comparison of the averages were chosen instead.
(v) Experimentation - This has been openly interpreted. Some people believe this factor refers to using results of
experiments, such as clinical trials, while others consider it to correspond to investigating the outcome from when a
patient has a repeat of the antecedent event [36]. For the latter, in the context of ADRs, it is clear that when a patient
experiences an ADR it will occur every time after the drug is ingested (under the same conditions) but should not be
present when the drug stops being ingested. Therefore, if the drug is prescribed two or more distinct times (break
of 12 months or more between prescriptions) for a patient and the medical event always follows but stops when the
drug stops, then this would be strong evidence to suggest a causal relationship. Therefore, we calculate the number
of people who experience Readcode j within a 1 to 30 day period after drugi for two or more distinct prescriptions
and never during the 1 to 30 day period before divided by the number of patients who have two or more distinct
prescriptions,
Attr
i, j
17
=
|{y
[1,30],i, j
k1
|y
[1,30],i, j
k1
∈
⋃
s,k
y
[1,30],i, j
s1
}
⋂
(
⋃
s
y
[−30,−1],i, j
s1
)c}|
|{y
i,.
k1
|y
i,.
k1
∈
⋃
s,k y
i,.
s1
}|
(9)
(vi)Hierarchal specific - We also propose features for dealing with the hierarchical medical event coding structures
found within THIN (and also in many other medical databases). The first feature is related to the noise caused by
patients taking multiple prescriptions. If a patient is taking more than one drug then the medical event may be caused
by the other drug, so the more drugs a patient is taking the higher the risk of confounding due to other drugs. The
noise value in the prescription vector tells us how many others drugs the patient has taken around the prescription, so
we calculate the average number of other drugs recorded within the 1 to 30 day period before or after drugi for the
patients experiencing Readcode j divided by the average over all prescriptions of drugi,
Attr
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) (10)
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To deal with the hierarchical structures we also generate features that can give insight into when the association might
correspond to a medical event that has previously been recorded but as a more general Read code. Firstly we calculate
the number of times the level 3 version of Readcode j is recorded for the first time ever within a 1 to 30 day period
after drugi divided by the number of times the level 4 version of Readcode j is recorded for the first time within the 1
to 30 day period after drugi,
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The final two features consider the temporality measure but when considering more general versions of the Read code.
These features calculate similar values to those used in the temporality section but when reducing all the Read codes
to their level 4 versions or level 3 versions respectively,
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After calculating the features for each drugi-Readcode j pair we have the corresponding feature vector Attr
i,j ∈
R
27, Attri,j = (Attr
i, j
1
, Attr
i, j
2
, ..., Attr
i, j
27
). The Bradford Hill consideration features are Attri,j ∈ R17, Attri,j =
(Attr
i, j
1
, Attr
i, j
2
, ..., Attr
i, j
17
). The hierarchal knowledge features are Attri,j ∈ R10, Attri,j = (Attr
i, j
18
, Attr
i, j
26
, ..., Attr
i, j
27
).
The association strength features are Attri,j ∈ R3, Attri,j = (Attr
i, j
1
, Attr
i, j
2
, Attr
i, j
3
).
The majority of the features described above investigate the 30 day period after the drug. This was due to our
problem focussing on signalling ADRs that occur within 30 days of the drug prescription. For signalling ADRs that
occur over a larger time period, the proposed features can simply be modified by adjusting the length of the time
period observed after the potential cause was recorded from [1, 30] to any time period of any length ([a,b]).
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Table 2: The feature subsets used for comparison to determine the usefulness of including more Bradford Hill consid-
erations and features related to the hierarchal structure of the database..
Method Number of features Feature set name Features included
SADR 27 All features Attr1 − Attr27
Comparison 1 17 Bradford Hill Attr1 − Attr17
Comparison 2 10 Hierarchal Attr18 − Attr27
Comparison 3 3 Association strength Attr1 − Attr3
2.2.3. Step 3: Train the classifier
After engineering the features for each of the drug-Read code pairs from the OMOP NSA reference set, where the
Read code was recorded at least 3 times within 30 days after the drug in THIN, we trained a random forest classifier.
To fairly evaluate the SADR framework, we decided to measure the trained classifier’s performance on each drug
separately. This was accomplished by creating 9 training/testing sets. Each training set contained all the data-points
for 8 of the drugs and its corresponding testing set contained all the data points for the remaining drug. If we trained
the classifier on all the labelled data then it would not be possible to validate that the classifier would work on new
data. However, leaving out the labelled data for one drug during training and then applying the trained classifier on the
left out drugs data to compare the prediction and truth is effectively mimicking the situation of applying the classifier
to new data.
The software used for the classification was R and the ‘caret’ [38] library. A parameter grid search was applied
to find the optimal number of parameters to use for each decision tree in the forest (the mtry parameter) and 10-fold
cross validation is implemented to reduce over fitting.
2.3. Evaluation Method
To investigate the importance of various proposed features, we investigate the performance of the SADR frame-
work (training a random forest using both the Bradford Hill consideration and hierarchal-based features) with a ran-
dom forest trained using only the Bradford Hill consideration based features or only the hierarchal features or only
the association strength features. Table 2 lists the various feature subsets investigated for comparison and details the
included features.
The performance measures we used were the same as in the previous study [39] using the NSA reference set to
enable a comparison. Using the classifiers prediction and the ground truth, the number of true positives (TP) is the
number of drug-HOIs where the classifier predicts the drug-HOIs are ADRs and the ground truth is that the drug-HOIs
are ADRs. The number of false positives (FP) is the number of drug-HOIs where the classifier predicts the drug-HOIs
are ADRs and the ground truth is that the drug-HOIs are non-ADRs. The number of false negatives (FN) is the number
of drug-HOIs where the classifier predicts the drug-HOIs are non-ADRs and the ground truth is that the drug-HOIs
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are ADRs. Finally, the number of true negatives (TN) is the number of drug-HOIs where the classifier predicts the
drug-HOIs are non-ADRs and the ground truth is that the drug-HOIs are non-ADRs.
The area under the receiver operating characteristic (ROC) curve (AUC) considers the trade off between the sensi-
tivity of the classification and the specificity. ROC curves are drawn by plotting the sensitivity (TP/(TP+FN)) against
one minus the specificity (TN/(TN+FP)) at different threshold stringencies. The AUC of the ROC plot gives an indi-
cation of how well the classifier performs. To compare the classifiers the DeLong’s test at a 5% significance level [40]
is applied to the AUCs. The DeLong’s test is a nonparametric inference that is applied to determine whether the AUC
between two paired ROC curves is significantly different. The average precision (AP), precision at cutoff 10 (P10),
false positive rate (FPR=FP/(FP+TN)) and Recall5 (=TP/(TP+FN)) at a FPR of 5% are also calculated.
3. Results
3.1. Evaluation of the SADR framework
The results are presented in Table 3. The first three columns detail the data used for testing, stating which drug was
excluded from the training data and how many drug-Read code pairs corresponding to ADRs and non-ADRs (nADR)
were in the testing set. The next four columns detail the training set, the optimal mtry found by tuning the random
forest on the training set using 10-fold cross validation using the AUC as the performance measure and the classifier’s
AUC (plus standard deviation) obtained by the cross-validation. The final five columns present the various measures
of performance of the trained random forest on the test set (effectively its performance on new data). Figures 2-4 show
the ROC plots of the SADR framework.
The combination of Bradford Hill and hierarchal features used as inputs into a random forest for signalling ADRs
resulted in an average AUC of 0.862 and MAP of 0.640 across all nine drug test sets. The top 10 drug-Read code pairs
ranked by the classifier’s confidence of the pair belonging to the ADR class were all true ADRs for 6 out of the 9 drug
test sets. The FPR ranged between 0.000 to 0.026 at the classifier’s natural threshold and at a 5% FPR the average
recall was 0.583.
3.2. Comparison of the SADR framework against random forests with other feature sets
The SADR framework (random forest using all the Bradford Hill and hierarchal features) had higher minimum,
maximum and mean AUCs, 0.792, 0.940 and 0.862 respectively, across the 9 test sets compared to the random
forests using only the Bradford Hill features (comparison 1), only the hierarchal features (comparison 2) or only the
association strength features (comparison 3), see Table 4. The p-values comparing the AUC of the SADR framework
with the three comparisons for each drug test set are displayed in Table 5. The SADR framework was significantly
better than the random forest using association strength features for all drugs except the Tricyclic antidepressants,
although this p-value approached significance (0.0584). The SADR framework was significantly better than the
random forest using the hierarchal features for the majority of drugs (6 out of the 9 drugs). However, the SADR
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Table 3: Performance of SADR framework when trained on 8 of the drugs and tested on the remaining drug. The
mtry is the value corresponding to the optimal training model’s mtry returned by the grid search when 10-fold cross
validation is implemented.
Test Set Training Set & Performance Test Set Results
Drug ADR nADR ADR nADR mtry AUC (SD) AUC AP P10 FPR Recall5
OMOP Benzodiazepines 36 342 369 3502 5 0.871(0.035) 0.940 0.730 1.000 0.003 0.611
OMOP Antiepileptics 41 403 364 3441 5 0.879(0.045) 0.792 0.442 0.700 0.007 0.439
OMOP ACE Inhibitor 76 491 329 3353 5 0.877(0.030) 0.875 0.711 1.000 0.002 0.592
OMOP Bisphosphonates 44 258 361 3586 5 0.870(0.039) 0.795 0.550 0.800 0.016 0.477
OMOP Beta blockers 38 492 367 3352 5 0.867(0.045) 0.922 0.766 1.000 0.004 0.711
OMOP Warfarin 33 313 372 3531 10 0.881(0.036) 0.863 0.704 1.000 0.000 0.606
OMOP Typical antipsychotics 40 301 365 3543 5 0.874(0.039) 0.883 0.728 1.000 0.007 0.675
OMOP Tricyclic antidepressants 54 425 351 3419 5 0.883(0.039) 0.828 0.598 1.000 0.005 0.574
OMOP Antibiotics 43 819 362 3025 15 0.879(0.037) 0.862 0.533 0.800 0.026 0.558
Overall Average - - - - - - 0.862 0.640 0.922 0.008 0.583
∗The ADR and nADR columns indicate the number of drug-outcome pairs labelled as ADRs or non-ADRs in the test/training sets.
framework was only significantly better than the random forest using the Bradford Hill features for 4 out of the 9
drugs.
3.3. Feature Importance
The importance of the features is presented in Table 6. Interestingly the feature chosen as the most important is
the experimentation feature (68.7 importance), followed by the association strength (44.6-47.9 importance) and the
hierarchal features based on noise or the ratio to how often the Read code level 3 version occurs for the first time
after the drug compared to the level 4 version. The highest of the specificity features is the average age of the patients
prescribed any drug that experience the Read code divided by the average of the patients prescribed the drug. In
Table 4: Summary of the performances of the SADR framework compared with random forests trained on various
subsets of the features proposed in Section 2.2.2 across the 9 drug test sets.
Method Feature Set Min AUC Max AUC Average AUC
SADR Bradford Hill & Hierarchal 0.792 0.940 0.862
Comparison 1 Bradford Hill 0.737 0.900 0.830
Comparison 2 Hierarchal 0.721 0.869 0.787
Comparison 3 Strength Ensemble 0.637 0.797 0.742
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(a) Ace Inhibitors (b) Antibiotics
(c) Antiepileptics (d) Benzodiazepines
Figure 2: Reciever operating characteristic curve plots for the different drug test sets. Comparison between SADR
framework (all features), Comparison 1 (Bradford Hill features only), Comparison 2 (hierarchal features only) and
Comparison 3 (Association strength features only).
16
/ 00 (2015) 1–27 17
(a) Betablockers (b) Bisphosphonates
(c) Tricyclic antidepressants (d) Typical antipsychotics
Figure 3: Reciever operating characteristic curve plots for the different drug test sets. Comparison between SADR
framework (all features), Comparison 1 (Bradford Hill features only), Comparison 2 (hierarchal features only) and
Comparison 3 (Association strength features only).
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Table 5: The p-values from the DeLong’s bootstrap test to compare the AUC for the paired ROC curves between the
SADR framework and each comparison.
Test Set Comparison 1(Bradford Hill) Comparison 2 (Hierarchal) Comparison 3 (Strength Ensemble)
OMOP Benzodiazepines 0.0046 0.0000 0.0000
OMOP Antiepileptics 0.8309 0.0445 0.0025
OMOP ACE Inhibitor 0.2307 0.0000 0.0116
OMOP Bisphosphonates 0.0010 0.1410 0.0000
OMOP Beta blockers 0.1033 0.0095 0.0000
OMOP Warfarin 0.0045 0.0115 0.0129
OMOP Typical antipsychotics 0.4236 0.0019 0.0011
OMOP Tricyclic antidepressants 0.3258 0.0755 0.0584
OMOP Antibiotics 0.0028 0.1974 0.0004
Figure 4: Reciever operating characteristic curve plots for the Warfarin test set.
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general, the features that considered all the drug prescriptions tended to have a higher average gini decrease value.
The hierarchal features investigating how many time the level 3 version of the Read code occurs 30 days after
the drug compared to 30 days before had the lowest mean gini decrease, ranging between 3.6 to 6. Apart from these
features, all the other features seem to be useful for the model as they had average gini decrease values greater than
10.
4. Discussion
The results show that the SADR framework (a random forest using feature engineering based on the Bradford Hill
considerations and hierarchal clinical codings) leads to the optimal classifier for discriminating between causality and
association. This suggests that using the proposed features can enable supervised learning to be applied successfully
to the problem of signalling ADRs in longitudinal observational data. The SADR framework obtained an average
AUC of 0.862, a MAP of 0.640, an average FPR of 0.008 and an average recall at 5% FPR of 0.583 on the OMOP
NSA reference set. In previous studies the Highthroughput Screening by Indiana University obtained the highest AUC
of 0.734 [39], with MAP, FPR and recall at 5% FPR scores of 0.141, 0.266 and 0.367 respectively. This shows that a
supervised approach made possible by the feature engineering can lead to improved ADR signalling. The supervised
approach achieved a much lower false positive rate meaning it is extremely unlikely to signal non-ADRs.
Although the supervised approached outperformed the unsupervised methods, it may be argued that the additional
complexity of the supervised approach makes it less suitable. However, we purposely suggested simple features that
are quick to calculate and do not require tuning (e.g., once you know what time period of interest to investigate [a, b],
there are no parameters to tune when calculating the features). Conversely, the existing unsupervised methods are
generally more complex and often have parameters that need to be tuned for new datasets and this requires applying
the methods numerous times. It is the data extraction and calculation of association strength (such as risk) from
the big longitudinal observational data is often the time consuming aspect of both the unsupervised and supervised
methods. Due to the simplicity of our proposed features, the framework combining the proposed feature engineering
and classification is actually likely to be quicker that the existing unsupervised methods. In addition, the simplicity
of the features also means that they could be calculated using distributed computing tool such as Hadoop [41]. In
theory, this would make the feature extraction scalability quasi-linear and could make the framework suitable for
many terabytes of data.
Another advantage of the simplicity of the features is that it enables them to the updated efficiently with the
addition of new data. For example, if we stored the number of patients prescribed the drug who experience the Read
code within 30 days (n1) as well as the average age of the patients prescribed the drug who experience the Read code
within 30 days avAge1, when new data are added we can simply calculate how many new occurrences of the Read
code occur within 30 days of the drug n2 and the average ages of these avAge2 to quickly update the new values
n = n1 + n2, avAge = (n1 ∗ avAge1 + n2 ∗ avAge2)/(n1 + n2). This means we only have to extract the features on the
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Table 6: The importance of the features within the random forest based on the total decrease in Gini impurity
Category Set Att Gini decrease
Experimentation X Attr17 68.7
Association Z Attr3 47.9
Association X Attr1 46.7
Association Y Attr2 44.6
Heirarchal X Attr18 41.7
Heirarchal X Attr21 33.2
Specificity X Attr4 29.6
Heirarchal Y Attr19 28.5
Heirarchal Z Attr20 28.4
Specificity X Attr7 25.8
Specificity Y Attr5 25.0
Specificity Z Attr6 23.0
Heirarchal X Attr22 21.4
Specificity Z Attr9 21.2
Specificity Y Attr8 20.5
Temporality X Attr11 20.4
Biological Gradient X Attr14 19.7
Heirarchal Z Attr26 16.9
Biological Gradient Y Attr15 16.6
Heirarchal Y Attr24 16.5
Biological Gradient Z Attr16 16.4
Temperality Y Attr12 14.1
Temporality Z Attr13 13.2
Specificity - Attr10 11.0
Heirarchal Z Attr27 6.0
Heirarchal Y Attr25 5.0
Heirarchal X Attr23 3.6
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big data once, and then we can update the features with the addition of small amounts of new data.
Interestingly, the results showed that the experimentation feature seemed to be good at discriminating between
causal and non-causal relationships. It is widely accepted that randomised controlled trials, a form of experimenta-
tion, are the best way to identify causality. The results of this paper suggest there may be ways to use longitudinal
observational data to perform a weak form of experimentation that is still informative. The hierarchal feature cor-
responding to how many other drugs a patient has around the time of prescription could actually be interpreted as
corresponding to the original specificity definition. If a patient is only taking one drug, then the relationship between
the drug and health outcome is more specific. This was an influential feature in the random forest, which suggests the
original specificity definition may have merit, although many have argued against its use.
In this paper we did not consider any coherence, plausibility or consistency features. The consistency features
could be generated by using alternative data, such as spontaneous reporting system databases, and calculating the
association strength for the drug and medical event pair within that data. The plausibility and coherence features may
be possible by using the chemical structure data, as this may indicate chemical structures that are associated to an
ADR or by adding a human feedback loop where a medical expert can identify incorrectly labelled pairs. Another
possibility to engineer features for plausibility would be to implement a crowd sourcing algorithm that can extract
suspected ADRs from online forums or medical literature.
It is worth noting that the Bradford Hill considerations are known to be limited and are consider only as a guide for
inferring causality [42]. The Bradford Hill considerations are not definitive criteria for causality and any limitation in
discriminating between causal and non-causal relationships using these considerations will also likely be a limitation
of the SADR framework. However, machine learning techniques such as random forest can identify complex patterns,
ones that are unlikely to be identified by humans, which may reduce the limitations of the considerations compared to
when they are implemented manually.
One final comment, is that the performance of supervise learning techniques will generally improve as the number
of labelled data to train on increases. Therefore, the proposed framework is expected to improve over time as more
labelled data becomes available.
5. Conclusion
In this paper we proposed a novel supervised ADR signalling framework (SADR) utilising Bradford Hill’s causal-
ity considerations to enable the implementation of a classifier that can accurately signal ADRs in big longitudinal
observational databases that suffer from confounding and have hierarchal clinical code structures. The framework
trains a random forest to discriminate between ADRs and non-ADRs using suitable features based on the Bradford
Hill causality considerations (many of which have been previously used to signal ADRs but never combined). The
trained random forest performed well at distinguishing between ADRs and non-ADRs when validated on the OMOP
NSA reference set (AUC ranging between 0.792 and 0.940). The classifier’s performance was better than existing
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unsupervised methods’ performances calculated in previous studies [39] highlighting the advantages of implementing
supervised learning for signalling ADRs.
Suggested future areas of work are expanding the feature engineering to include the remaining Bradford Hill
causality considerations (analogy, consistency, plausibility and coherence) and using the Map-Reduce paradigm to
enable the extraction of the features in quasi-linear scalability, making this framework suitable for terabytes of big
healthcare data.
Appendix A. Feature Summaries
Table A.7: Summary of the features used within the SADR framework.
Feature Category Description
Attr1 Strength The fraction of patients experiencing the health outcome within 30 days of the drug
minus the fraction of patients experiencing the health outcome within 30 days of any
other drug
Attr2 Strength The fraction of patients experiencing the health outcome within 30 days of any first time
prescription in 13 months of the drug minus the fraction of patients experiencing the
health outcome within 30 days of a first time prescription in 13 months of any other drug
Attr3 Strength The fraction of patients experiencing the health outcome within 30 days of any first
time prescription of a drug family minus the fraction of patients experiencing the health
outcome within 30 days of a first time prescription of any other drug family.
Attr4 Specificity The average age of patients experiencing the health outcome within 30 days of the drug
divided by the average age of patients prescribed the drug
Attr5 Specificity The average age of patients experiencing the health outcome within 30 days of any first
time prescription in 13 months of the drug divided by the average age of patients first
time prescriptions in 13 months of the drug.
Attr6 Specificity The average age of patients experiencing the health outcome within 30 days of any first
time prescription of the drug family divided by the average age of patients first time
prescription of the drug family
Attr7 Specificity The fraction of patients that are male out of those experiencing the health outcome within
30 days of the drug divided by the male fraction of patients prescribed the drug
Continued on next page
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Table A.7 – Continued from previous page
Feature Category Description
Attr8 Specificity The fraction of patients that are male out of those experiencing the health outcome within
30 days of any first time prescription in 13 months of the drug divided by the fraction
of patients prescriptions corresponding to the first time prescription in 13 months of the
drug where the patient is male
Attr9 Specificity The fraction of patients that are male out of those experiencing the health outcome within
30 days of any first time prescription of the drug family divided by the fraction of patients
prescriptions corresponding to the first time prescription of the drug family where the
patient is male
Attr10 Specificity The hierarchal level of the Read code (this corresponds to how specific the health out-
come is)
Attr11 Temporality The number of times the heath outcome occurs within 1 and 30 days after a prescription
of the drug divided by the number of times the heath outcome occurs within 1 and 30
days before a prescription of the drug
Attr12 Temporality The number of times the heath outcome occurs within 1 and 30 days after a first time in
13 months prescription of the drug divided by the number of times the heath outcome
occurs within 1 and 30 days before a first time in 13 months prescription of the drug
Attr13 Temporality The number of times the heath outcome occurs within 1 and 30 days after a first time
prescription of the drug family divided by the number of times the heath outcome occurs
within 1 and 30 days before a first time prescription of the drug family
Attr14 Biological
gradient
The average drug dosage given to patients experiencing the health outcome within 30
days of the drug divided by the average drug dosage given to patients prescribed the
drug
Attr15 Biological
gradient
The average drug dosage given to patients experiencing the health outcome within 30
days of any first time prescription in 13 months of the drug divided by the average drug
dosage given to patients when considering their first time prescription in 13 months of
the drug.
Attr16 Biological
gradient
The average drug dosage given to patients experiencing the health outcome within 30
days of any first time prescription of the drug family divided by the average drug dosage
given to patients when considering their first time prescription of the drug family
Continued on next page
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Table A.7 – Continued from previous page
Feature Category Description
Attr17 ExperimentationThe number of patients who were prescribe the drug and experienced the health outcome
within 1 and 30 days after on two or more distinct time periods (with 13 months or more
between consecutive prescriptions of the drug) but never experienced the health outcome
within 1 and 30 days prior to any prescription of the drug divided by the number of
patients with multiple distinct prescription periods (with two or more drug prescriptions
with a gap of 13 months of more between consecutive prescriptions).
Attr18 Hierarchal The average number of other drugs prescribed during the 30 days before and after the
drug prescription for the prescriptions where the patient experienced the health outcome
within 1 and 30 days after the prescription divided by the average number of other drugs
prescribed during the 30 days before and after the drug prescription for all prescriptions
of the drug.
Attr19 Hierarchal The average number of other drugs prescribed during the 30 days before and after any
first time in 13 month prescription of the drug where the patient experienced the health
outcome within 1 and 30 days after the prescription divided by the average number of
other drugs prescribed during the 30 days before and after the drug prescription for any
first time in 13 months prescription of the drug.
Attr20 Hierarchal The average number of other drugs prescribed during the 30 days before and after any
first time prescription of the drug family where the patient experienced the health out-
come within 1 and 30 days after the prescription divided by the average number of other
drugs prescribed during the 30 days before and after the drug prescription for any first
time prescription of the drug family.
Attr21 Hierarchal The number of prescriptions where the patient has the health outcome recorded within
1 and 30 days after the drug but the patient has never had a similar but more general
version of the health outcome recorded (level 4 version read code) divided by the number
of prescriptions where the patient has the health outcome recorded within 1 and 30 days
after the drug but the patient has never had a similar but even more general version of
the health outcome recorded (level 3 version read code).
Attr22 Hierarchal The number of prescriptions where the patient has the more general level 4 version of
the health outcome recorded within 1 and 30 days after the drug prescription divided by
the number of prescriptions where the patient has the more general level 4 version of the
health outcome recorded within 1 and 30 days before the drug prescription.
Continued on next page
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Table A.7 – Continued from previous page
Feature Category Description
Attr23 Hierarchal The number of prescriptions where the patient has the more general level 3 version of
the health outcome recorded within 1 and 30 days after the drug prescription divided by
the number of prescriptions where the patient has the more general level 3 version of the
health outcome recorded within 1 and 30 days before the drug prescription.
Attr24 Hierarchal The number of prescriptions where the patient has the more general level 4 version of the
health outcome recorded within 1 and 30 days after the first time in 13 month prescription
of the drug divided by the number of prescriptions where the patient has the more general
level 4 version of the health outcome recorded within 1 and 30 days before the first time
in 13 months prescription of the drug.
Attr25 Hierarchal The number of prescriptions where the patient has the more general level 3 version of the
health outcome recorded within 1 and 30 days after the first time in 13 month prescription
of the drug divided by the number of prescriptions where the patient has the more general
level 3 version of the health outcome recorded within 1 and 30 days before the first time
in 13 months prescription of the drug.
Attr26 Hierarchal The number of prescriptions where the patient has the more general level 4 version of the
health outcome recorded within 1 and 30 days after the first time prescription of the drug
family divided by the number of prescriptions where the patient has the more general
level 4 version of the health outcome recorded within 1 and 30 days before the first time
prescription of the drug family.
Attr27 Hierarchal The number of prescriptions where the patient has the more general level 3 version of the
health outcome recorded within 1 and 30 days after the first time prescription of the drug
family divided by the number of prescriptions where the patient has the more general
level 3 version of the health outcome recorded within 1 and 30 days before the first time
prescription of the drug family.
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